Showing results (461-470 of 554) with videos related to
Sort By:
Pageof 56
European Urology|July 27, 2023
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 StudyElizabeth R Plimack, Thomas Powles, Viktor Stus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2003
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trialJoseph I Clark, Michael B Atkins, Walter J Urba, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell CarcinomaDavid F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.Journal for Immunotherapy of Cancer|July 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.Journal of the National Cancer Institute|May 3, 2020
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational ResearchToni K Choueiri, Michael B Atkins, Ziad Bakouny, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2001
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging systemC M Balch, S J Soong, J E Gershenwald, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2001
Final version of the American Joint Committee on Cancer staging system for cutaneous melanomaC M Balch, A C Buzaid, S J Soong, et al.CA: a Cancer Journal for Clinicians|June 16, 2004
An evidence-based staging system for cutaneous melanomaCharles M Balch, Seng-Jaw Soong, Michael B Atkins, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2020
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell CarcinomaMichael B Atkins, Brian I Rini, Robert J Motzer, et al.Pageof 56